-
1 Comment
Omnicell, Inc is currently in a long term uptrend where the price is trading 23.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Omnicell, Inc's total revenue rose by 0.4% to $249M since the same quarter in the previous year.
Its net income has dropped by 25.9% to $16M since the same quarter in the previous year.
Finally, its free cash flow grew by 255.8% to $71M since the same quarter in the previous year.
Based on the above factors, Omnicell, Inc gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Exchange | F |
CurrencyCode | EUR |
ISIN | US68213N1090 |
Industry | Health Information Services |
Market Cap | 1B |
---|---|
PE Ratio | 110.0 |
Target Price | 167.5 |
Beta | 0.79 |
Dividend Yield | None |
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital; and specialized automated dispensing systems for hospitals, health systems, and post-acute care facilities. It also provides central pharmacy dispensing services; IV compounding services; turnkey solution designed to help health systems establish, manage, and optimize an entity-owned specialty pharmacy, as well as support onsite management of specialty pharmacy services, including payer contracting, staffing, licensing, and 340B program administration. In addition, the company offers inventory optimization services comprising predictive and prescriptive analytics, benchmarking, workflow tools, and clinical resources, as well as medication inventory visibility; patient engagement, clinical, and financial solutions; medication adherence solutions, which include single-dose automation solutions, automated and semi-automated filling equipment, various medication blister card packaging and packaging supplies; and software that guides users through the manual filling process. Further, it provides professional services, such as technology installation, program management, customer education and training, change management services, and related offerings; technical services comprising post-installation support and maintenance via phone and/or web, on-site service, parts, and access to software upgrades; and retail pharmacy and hospital automation outside the United States business. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. The company was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for OC9.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025